{"id":2695,"date":"2018-10-30T10:26:55","date_gmt":"2018-10-30T14:26:55","guid":{"rendered":"https:\/\/www.med.unc.edu\/medicine\/infdis\/actu\/?page_id=2695"},"modified":"2018-11-06T20:43:04","modified_gmt":"2018-11-07T01:43:04","slug":"investigational-medication-cure-studies","status":"publish","type":"page","link":"https:\/\/www.med.unc.edu\/medicine\/infdis\/actu\/current-studies-2\/hiv-cure-related-studies\/investigational-medication-cure-studies\/","title":{"rendered":"Investigational Medication CURE Studies"},"content":{"rendered":"<div class=\"entry-content-asset\"><iframe loading=\"lazy\" width=\"1140\" height=\"641\" src=\"https:\/\/www.youtube.com\/embed\/ql-aCSTTKeA?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen><\/iframe><\/div>\n<h3>XTRA<\/h3>\n<table style=\"height: 170px\" border=\"1\">\n<tbody>\n<tr style=\"height: 42px\">\n<td style=\"width: 214px;height: 42px\"><strong>Goal<\/strong><\/td>\n<td style=\"width: 844px;height: 42px\">The combination of HXTC therapy and multiple doses of VOR will result in a depletion of persistent, latent, replication competent HIV infection.<\/td>\n<\/tr>\n<tr style=\"height: 62px\">\n<td style=\"width: 214px;height: 62px\"><strong>Who is eligible to participate<\/strong><\/td>\n<td style=\"width: 844px;height: 62px\">HIV-infected men and women, \u226518 and &lt; 65 years of age, with durable viral suppression as measured on standard HIV RNA assays for \u226524 months. Eligible participants must be on stable combination ART (cART) and have a CD4 count \u2265350 cells\/mm3.<\/td>\n<\/tr>\n<tr style=\"height: 22px\">\n<td style=\"width: 214px;height: 22px\"><strong>Medication<\/strong><\/td>\n<td style=\"width: 844px;height: 22px\">Vorinostat and Expanded Specific T-Cell Therapy<\/td>\n<\/tr>\n<tr style=\"height: 22px\">\n<td style=\"width: 214px;height: 22px\"><strong>Duration<\/strong><\/td>\n<td style=\"width: 844px;height: 22px\">Up to 48 months<\/td>\n<\/tr>\n<tr style=\"height: 22px\">\n<td style=\"width: 214px;height: 22px\"><strong>Compensation<\/strong><\/td>\n<td style=\"width: 844px;height: 22px\">Total: $3700. Travel &amp; parking compensation are offered as well.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<h3>DART<\/h3>\n<table style=\"height: 160px;width: 1056px\" border=\"1\">\n<tbody>\n<tr style=\"height: 42px\">\n<td style=\"width: 205.9px;height: 42px\"><strong>Goal<\/strong><\/td>\n<td style=\"width: 849.267px;height: 42px\">Characterize the safety and tolerability of MGD014 administered intravenously (IV) to HIV-infected participants maintained on suppressive ART.<\/td>\n<\/tr>\n<tr style=\"height: 42px\">\n<td style=\"width: 205.9px;height: 42px\"><strong>Who is eligible to participate<\/strong><\/td>\n<td style=\"width: 849.267px;height: 42px\">HIV-1-infected adults (18 to 65 years old) on ART with plasma HIV RNA &lt; 50 copies\/mL for 24 months prior to enrollment.Eligible participants must be on stable combination ART (cART) and have a CD4 count \u2265 350 cells\/mm3.<\/td>\n<\/tr>\n<tr style=\"height: 22px\">\n<td style=\"width: 205.9px;height: 22px\"><strong>Medication<\/strong><\/td>\n<td style=\"width: 849.267px;height: 22px\">MGD014 administered via a single infusion in Part 1 or a weekly infusion, for 6 weeks, in Part 2<\/td>\n<\/tr>\n<tr style=\"height: 22px\">\n<td style=\"width: 205.9px;height: 22px\"><strong>Duration<\/strong><\/td>\n<td style=\"width: 849.267px;height: 22px\">10 weeks (Part 1) or 20 weeks (Part 2)<\/td>\n<\/tr>\n<tr style=\"height: 32px\">\n<td style=\"width: 205.9px;height: 32px\"><strong>Compen<\/strong><strong>sation<\/strong><\/td>\n<td style=\"width: 849.267px;height: 32px\">Part 1: Step 1 &#8211; $100, Step 2 &#8211; up to $750, Step 3 &#8211; $150, Total &#8211; up to $1000.<\/p>\n<p>Part 2: Step 1 &#8211; $300, Step 2 &#8211; $1350, Step 3 &#8211; $400, Total &#8211; $2050.<\/p>\n<p>Travel &amp; parking compensation are offered as well.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<h3>A5377<\/h3>\n<table style=\"width: 1056px\" border=\"1\">\n<tbody>\n<tr>\n<td style=\"width: 183.933px\"><strong>Goal<\/strong><\/td>\n<td style=\"width: 871.233px\">The purpose of this study is to test a drug that has not been tested in humans before now. This experimental drug is called SAR441236.<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 183.933px\"><strong>Who is eligible to participate<\/strong><\/td>\n<td style=\"width: 871.233px\">HIV infected men and women who have never received ART or who have taken ART for &gt; 12 months<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 183.933px\"><strong>Medication<\/strong><\/td>\n<td style=\"width: 871.233px\">SAR441236 via 1- 4 IV infusions<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 183.933px\"><strong>Duration<\/strong><\/td>\n<td style=\"width: 871.233px\">4-18 months<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 183.933px\"><strong>Compen<\/strong><strong>sation<\/strong><\/td>\n<td style=\"width: 871.233px\">Visits &#8211; $50, Infusion visits with PK &#8211; $250. Arm A, groups 1-3, Total &#8211; $800. Arm A, group 4, Total &#8211; $1,950. Arm B, all groups, Total &#8211; $850. Travel &amp; parking compensation are offered as well.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<p>For information about additional studies that are coming soon please visit <a href=\"https:\/\/www.med.unc.edu\/medicine\/infdis\/actu\/current-studies\/coming-soon\/\">here<\/a>.<\/p>\n <button type=\"button\" class=\"btn btn-primary btn-sm\" data-toggle=\"modal\" data-target=\"#myModal-1\">How can I participate?<\/button>\n\n<div class=\"modal fade\" id=\"myModal-1\" tabindex=\"-1\" aria-labelledby=\"myModalLabel\" aria-hidden=\"true\">\n  <div class=\"modal-dialog\">\n    <div class=\"modal-content\">\n      <div class=\"modal-header\">\n        <button type=\"button\" class=\"close\" data-dismiss=\"modal\" aria-label=\"Close\"><span aria-hidden=\"true\">&times;<\/span><\/button>\n        <h4 class=\"modal-title\" id=\"myModalLabel\">Are you interested in potentially participating in one of our studies?<\/h4>\n      <\/div>\n      <div class=\"modal-body\">\n        To learn more about our current studies please fill out our online form <a href=\"https:\/\/www.med.unc.edu\/medicine\/infdis\/actu\/contact-us\/\">here<\/a>, or call us at (919) 445-2772. Thank you!\n      <\/div>\n    <\/div>\n  <\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>XTRA Goal The combination of HXTC therapy and multiple doses of VOR will result in a depletion of persistent, latent, replication competent HIV infection. Who is eligible to participate HIV-infected men and women, \u226518 and &lt; 65 years of age, with durable viral suppression as measured on standard HIV RNA assays for \u226524 months. Eligible &hellip; <a href=\"https:\/\/www.med.unc.edu\/medicine\/infdis\/actu\/current-studies-2\/hiv-cure-related-studies\/investigational-medication-cure-studies\/\" aria-label=\"Read more about Investigational Medication CURE Studies\">Read more<\/a><\/p>\n","protected":false},"author":70584,"featured_media":0,"parent":2687,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-2695","page","type-page","status-publish","hentry","odd"],"acf":[],"_links_to":[],"_links_to_target":[],"_links":{"self":[{"href":"https:\/\/www.med.unc.edu\/medicine\/infdis\/actu\/wp-json\/wp\/v2\/pages\/2695","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.unc.edu\/medicine\/infdis\/actu\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.med.unc.edu\/medicine\/infdis\/actu\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/infdis\/actu\/wp-json\/wp\/v2\/users\/70584"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/infdis\/actu\/wp-json\/wp\/v2\/comments?post=2695"}],"version-history":[{"count":0,"href":"https:\/\/www.med.unc.edu\/medicine\/infdis\/actu\/wp-json\/wp\/v2\/pages\/2695\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/infdis\/actu\/wp-json\/wp\/v2\/pages\/2687"}],"wp:attachment":[{"href":"https:\/\/www.med.unc.edu\/medicine\/infdis\/actu\/wp-json\/wp\/v2\/media?parent=2695"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}